Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fighting HIV with antibodies

09.04.2015

30 years after HIV was discovered to be the cause of the acquired immune deficiency syndrome (AIDS), and despite intensive research, no vaccine or cure has yet been found. 

An international team of scientists, in collaboration with the German Center for Infection Research (DZIF) and the University Hospital of Cologne, has now tested a new generation of antibodies in humans for the first time. They have demonstrated that these broadly neutralising antibodies significantly reduce the number of human immunodeficiency viruses (HIV) in infected patients’ blood. The results have been published in the renowned journal Nature.


Fighting HIV with Antibodies

Zach Veilleux, Rockefeller University

Today, HIV infections can be well controlled with a combination of different antiviral drugs. However, the drugs can cause some severe side effects, are expensive and have to be taken over a lifetime. Additionally, resistance can develop, which challenges individual treatment. “This is why we still need new treatment options,” explains Cologne infectious diseases specialist Prof Gerd Fätkenheuer, who is researching new ways of treating and preventing AIDS at the German Center for Infection Research.

In the trial, published today in Nature, doctors from the University Hospital of Cologne together with researchers of Michel Nussenzweig’s Laboratory from Rockefeller University in New York (USA) investigated a new treatment approach. For the first time, the scientists conducted human trials with an antibody (3BNC117), which was developed previously in Nussenzweig laboratory.

The special thing about this antibody is its ability to neutralise a large number of different human immunodeficiency viruses effectively. In the trial, which was co-funded by the DZIF, the antibody showed good tolerability and favourable pharmacological properties.

Furthermore, patients undergoing treatment at the highest dose level (30 mg per kg of bodyweight) showed a significant drop in viral load. “With this, the antibody has a potency comparable to the drugs we are currently using for treatment,” Fätkenheuer explains. The treatment effects could be observed for up to 28 days after administration of the antibodies.

The trial consequently opens up a new field in HIV treatment. Co-First Author Prof Florian Klein, who will soon be changing from the Rockefeller University to the University Hospital of Cologne, sees particular potential in the mechanism of action of broadly neutralising antibodies: “Neutralising antibodies have a different mechanism of action and different pharmacological properties compared to the HIV drugs that have been used up to now.”

According to the scientists, “Neutralising antibodies could play an important role in HIV treatment and HIV prevention.” Plans for clinical trials investigating the efficacy of broadly neutralising antibodies with regard to curing HIV are currently underway.

Current publication
Caskey, M.*; Klein, F.*(*Co-First Authors); Lorenzi, J.C.C.; Seaman, M.S.; West, A.P., Jr, Buckley, N.; Kremer, G.; Nogueira, L.; Braunschweig, M.; Scheid, J.F.; Horwitz, J. A.; Shimeliovich, I.; Avraham-Shulman, S.B.; Witmer-Pack, M.; Platten, M., Lehmann, C.; Burke, L.A.; Hawthorne, T.; Gorelick, R.J.; Walker, B.D.; Keler, T.; Gulick, R.M., Fätkenheuer, G.; Schlesinger, S.J.; Nussenzweig, M.C.:
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Nature, online first released on April 08 (2015)
DOI: 10.1038/nature14411

Contact
Prof Gerd Fätkenheuer
E-mail: g.faetkenheuer@uni-koeln.de

Prof Florian Klein
T +12123278367 /Mobile +17182900235
E-mail: fklein@rockefeller.edu

DZIF Press Office
Karola Neubert and Janna Schmidt
T +49531-6181-1170/1154
E-mail: presse@dzif.de

Press Office University Hospital of Cologne
Christoph Wanko
T +49221-478-88757
E-mail: Christoph.wanko@uk-koeln.de

Karola Neubert | idw - Informationsdienst Wissenschaft
Further information:
http://www.uk-koeln.de/

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>